This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.

AstraZeneca, Oxford aim to produce Omicron-targeted vaccine

AstraZeneca Plc (AZN.L) said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine.

"Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data," a spokesperson for the company said in a statement.

Oxford did not immediately respond to a request for comment outside business hours.

The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford.

"Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised," Douglas told FT.

A lab-study last week found that AstraZeneca's antibody cocktail Evusheld retained neutralising activity against the Omicron variant.

Vaccine makers Pfizer/BioNTech (PFE.N), (22UAy.DE) and Moderna (MRNA.O) also previously said they were working on Omicron- specific COVID-19 vaccines. Moderna said hopes to start clinical trials early next year.

Source: Reuters / Reporting by Maria Ponnezhath in Bengaluru; Additional reporting by Vishal Vivek; Editing by Leslie Adler, David Gregorio and Sonya Hepinstall

Author: NIdhul   

Share This Post

related posts

On Top